Loading institutional data...
Loading institutional data...
Held by 179 of 5,944 reporting institutions (91th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
2/7 of the 9 checks — 2 couldn't be scored (see above), so the score is out of the 7 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$164M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest expense isn't separately reported — often netted into “other income (expense), net.”
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-17
Where each multiple sits in its own 14-yr range · 25th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| R&D | 10595.1 | 6245.2 | 8778.9 | 41.0 | 251.5 | 241.4 | 164.6 | 1392.5 |
| SG&A | 4448.4 | 4390.2 | 4537.3 | 23.1 | 92.6 | 67.7 | 49.7 | 613.3 |
| Operating Income | -16634.0 | -10527.9 | -13216.2 | 35.9 | -244.1 | -209.1 | -114.4 | -2216.4 |
| Income Tax | -49.2 | 46.6 | -33.2 | 2.5 | -16.1 | -14.7 | -4.9 | 446.7 |
| Net Income | -16297.9 | -9542.6 | -13029.8 | 33.4 | -217.0 | -160.9 | -90.5 | -2520.6 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on PRTA: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.7M 100.0% | $135.2M 100.0% | $91.4M 100.0% | $53.9M 100.0% | $200.6M 100.0% | $853K 100.0% | $814K 100.0% | $955K 100.0% | $27.5M 100.0% | $1.1M 100.0% |
| Research & Development | $134.9M 1392.5% | $222.5M 164.6% | $220.6M 241.4% | $135.6M 251.5% | $82.3M 41.0% | $74.9M 8778.9% | $50.8M 6245.2% | $101.2M 10595.1% | $134.5M 488.9% | $119.5M 11330.2% |
| Selling, General & Admin | $59.4M 613.3% | $67.2M 49.7% | $61.8M 67.7% | $49.9M 92.6% | $46.3M 23.1% | $38.7M 4537.3% | $35.7M 4390.2% | $42.5M 4448.4% | $48.2M 175.2% | $41.1M 3891.6% |
| Total Operating Expenses | $224.3M 2316.4% | $289.7M 214.4% | $282.4M 309.1% | $185.5M 344.1% | $128.6M 64.1% | $113.6M 13316.2% | $86.5M 10627.9% | $159.8M 16734.0% | $182.8M 664.2% | $160.6M 15221.8% |
| Operating Income | -$214.6M -2216.4% | -$154.6M -114.4% | -$191.0M -209.1% | -$131.6M -244.1% | $72.0M 35.9% | -$112.7M -13216.2% | -$85.7M -10527.9% | -$158.9M -16634.0% | -$155.3M -564.2% | -$159.5M -15121.8% |
| Other Income (Expense), net | $13.8M 142.6% | $25.6M 19.0% | $30.6M 33.4% | $6.0M 11.0% | -$54K -0.0% | $1.3M 153.2% | $8.4M 1031.8% | $2.7M 286.9% | -$2.3M -8.5% | $571K 54.1% |
| Pretax Income | -$200.8M -2073.8% | -$128.9M -95.4% | -$160.5M -175.6% | -$125.6M -233.0% | $71.9M 35.9% | -$111.4M -13063.0% | -$77.3M -9496.1% | -$156.1M -16347.1% | -$157.6M -572.7% | -$159.0M -15067.7% |
| Income Tax Expense | $43.3M 446.7% | -$6.6M -4.9% | -$13.5M -14.7% | -$8.7M -16.1% | $4.9M 2.5% | -$283K -33.2% | $379K 46.6% | -$470K -49.2% | -$4.4M -15.9% | $1.1M 108.4% |
| Net Income | -$244.1M -2520.6% | -$122.3M -90.5% | -$147.0M -160.9% | -$116.9M -217.0% | $67.0M 33.4% | -$111.1M -13029.8% | -$77.7M -9542.6% | -$155.6M -16297.9% | -$153.2M -556.8% | -$160.1M -15176.1% |
| Per Share | ||||||||||
| EPS (Basic) | $-4.53 | $-2.27 | $-2.76 | $-2.47 | $1.51 | $-2.78 | $-1.95 | — | — | — |
| EPS (Diluted) | $-4.53 | $-2.27 | $-2.76 | $-2.47 | $1.38 | $-2.78 | $-1.95 | — | — | — |
| Weighted Avg Shares (Basic) | 53.8M | 53.8M | 53.2M | 47.4M | 44.2M | 39.9M | 39.9M | — | — | — |
| Weighted Avg Shares (Diluted) | 53.8M | 53.8M | 53.2M | 47.4M | 48.5M | 39.9M | 39.9M | — | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| PRTA | $455M | — | — | 47.0× | -92.8% | — | -2521% | -87.0% | -87.0% | — | 179 |
Peers = companies sharing PRTA's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.